Swedres 2007 Figures and tables Swedres 2007

Table 3.1.1. Total sales of antibacterial drugs for systemic use in Sweden 2000-2007, DDD/1000/day. Methenamine is an antiseptic and therefore of no interest regarding antibiotic resistance, even though the WHO Collaborating Centre for Drug Statistics methodology classifies it as an antibacterial drug. Swedres 2007

Figure 3.1.1. Antibiotics in community care, DDD/1000/day, with and without methenamine. Swedres 2007

Figure 3.1.2. Antibiotics in community care 2007, percent of total DDD/1000/day. *Methenamine represents more than 99% of the group ”Other antibacterials”. Swedres 2007

Figure 3.1.3. Antibiotics in community care 2005-2007, DDD/1000/day. *Methenamine use represents more than 99% of the group ”Other antibacterials”. Swedres 2007

Figure 3.1.4. Antibiotic use in community care in the 21 counties of Sweden. Prescriptions/1000/year, 2005-2007, J01 excl methenamine. Swedres 2007

Figure 3.1.5. Fraction of the population treated with at least one course of antibiotics (J01 excl methenamine) in community care in 2007. The 21 counties of Sweden, all ages, users/1000 inhabitants. Age and gender standardized data. Swedres 2007

Figure 3.1.6. Sales of antibiotics (J01 excl methenamine) in the 21 counties of Sweden 2005-2007. Children aged 0-6 years, community care, prescriptions/1000/year. Swedres 2007

Figure 3.1.7. Fraction of the population treated with at least one course of antibiotics (J01 excl methenamine) in comunity care in 2007. The 21 counties of Sweden, children aged 0-6 years, users/1000/children. Swedres 2007

Figure 3.1.8. Swedish municipalities with the highest and lowest fraction of children treated with at least one course of antibiotics (J01 excl methenamine) in community care in 2007. Children aged 0-6 years, users/1000. Red coloured municipalities are large in size, yellow coloured are of medium size and blue coloured are small municipalities. Swedres 2007

Figure 3.1.9. Antibiotics commonly used for respiratory tract infections. Prescriptions/1000/year, community care, 2000-2007. Swedres 2007

Figure 3.1.10. Antibiotics commonly used for respiratory tract infections, community care 2007. DDD/1000/day, age and gender standardized data. Swedres 2007

Figure 3.1.11. Antibiotics commonly used for urinary tract infections. Women aged 18 years or older, 2000-2007, prescriptions/1000/year. Swedres 2007

Table 3.1.2. Antibiotic use in hospital care, 2000-2007, DDD/1000/day. Swedres 2007

Figure 3.1.12. Antibiotics in hospital care 2007, percent of total DDD/1000/day. *Methenamine represents more than 98% of the group ”Other antibacterials”. Swedres 2007

Figure 3.1.13. Antibiotics in hospital care 2005-2007, DDD/1000/day. Swedres 2007

Figure 3.1.14. Tetracyclines (J01AA) in hospital care, all counties of Sweden 2006-2007, DDD/1000 inhabitants. Swedres 2007

Figure 3.1.15. Incidence of genital Chlamydia, all counties of Sweden 2006-2007, number of cases/1000 inhabitants. Sorted as figure 3.1.14. Swedres 2007

Table 3. 1. 4. Antibiotics in hospital care 1997-2006 Table 3.1.4. Antibiotics in hospital care 1997-2006. DDD/100 admissions. Swedres 2007

Table 3. 1. 5. Antibiotics in hospital care 1997-2006 Table 3.1.5. Antibiotics in hospital care 1997-2006. DDD/100 patient-days. Swedres 2007

Figure 3.1.16. Cephalosporins (J01DB-DE) in hospital care, all counties 2005-2007, DDD/100 patient-days. Denominator data for 2006 is also used for 2007. Swedres 2007

Figure 3.1.17. Cephalosporins in hospital care, all counties 2007 (denominator data from 2006), DDD/100 patient-days. Swedres 2007

Figure 3.1.18. Carbapenems (J01DH) in hospital care, all counties 2005-2007, DDD/100 patient-days. Denominator data for 2006 is also used for 2007. Swedres 2007

Figure 3.1.19. Total community antibiotic use (methenamine excluded) in some European countries, 1999-2006. DDD/1000/day. Source: ESAC Swedres 2007

Table 3.1.6. Number of reports to the Swedish Medical Products Agency 2003-2007. Swedres 2007

Table 3.1.7. Number of most frequently reported spontaneously reported adverse events for fluoroquinolones and nitrofurantoin during the period 2003-2007. Swedres 2007

Figure 3.2.1. Use of antifungals in hospital care, 2000-2007. Swedres 2007

Figure 4.1.1. Annual number of recorded screening samples 2001-2007. Swedres 2007

Figure 4.1.2. Number of MRSA notified anually by country of acquisition, Sweden 2000-2007. Domestic/Imported and Imported/Domestic means both alternatives possible, given in that order. Swedres 2007

Table 4.1.1. MRSA notified in 2000-2007 by county under the Communicable Disease Act. Swedres 2007

Figure 4.1.3. Age distribution of notified domestic cases of MRSA, Sweden 2000-2007. Swedres 2007

Figure 4.1.4. The culture indication for domestic and imported MRSA cases in Sweden 2006-2007. Swedres 2007

Figure 4.1.5. Source of MRSA acquisition by country of infection, Sweden 2006-2007. Swedres 2007

Table 4.1.2. Numbers and rates of resistance (%) to indicated antibiotics among MRSA strains 2000-2007. Swedres 2007

Figure 4. 1. 6. Resistance rates for S Figure 4.1.6. Resistance rates for S. aureus 2001-2007 (data from the annual RSQC programme, approximately 3000 isolates per year). *In 2005 resistance rates were recorded in S. aureus isolated from wounds and secretions from elderly people (>65 years). Swedres 2007

Table 4.1.3. S. aureus susceptibility results (number of strains and percentage) using the disk diffusion method and confirmation of the mecA gene according to SRGA in Sweden. Data reported from SMI to EARSS. Swedres 2007

Figure 4. 1. 7. Number of PNSP cases and annual incidence of S Figure 4.1.7. Number of PNSP cases and annual incidence of S. pneumoniae with reduced susceptibility to penicillin, MIC> 0.5 mg/L) in Sweden 1997-2007. Swedres 2007

Figure 4.1.8. Age distribution of all cases reported with PNSP in Sweden 1997-2007. Swedres 2007

Figure 4. 1. 9. Resistance rates for S Figure 4.1.9. Resistance rates for S. pneumoniae 1994-2007 (data from the annual RSQC programme, approximately 3000 isolates per year). Swedres 2007

Table 4.1.4. Invasive isolates of S. pneumoniae reported to EARSS. Swedres 2007

Table 4. 1. 5. Resistance in invasive isolates of E Table 4.1.5. Resistance in invasive isolates of E. faecalis reported to EARSS 2001-2007. Swedres 2007

Table 4. 1. 6. Resistance in invasive isolates of E Table 4.1.6. Resistance in invasive isolates of E. faecium reported to EARSS 2001-2007. Swedres 2007

Figure 4.1.10. Resistance rates (resistant isolates in percent of all S. pyogenes isolates) for three groups of antibiotics 1994-2007. Swedres 2007

Figure 4.1.11. The incidence of ESBL in Swedish counties. Swedres 2007

Figure 4.1.12.a. Age and gender distribution of E. coli cases. Swedres 2007

Figure 4.1.12.b. Age and gender distribution of K. pneumoniae cases. Swedres 2007

Figure 4.1.13. Resistance rates (resistant isolates in percent of all E. coli isolates) for six antibiotics 1996-2007. *Between 1996-2001 fluoroquinolone resistance was detected with Norfloxacin, from 2002 with Nalidixic acid. Swedres 2007

Table 4.1.7. E. coli from blood cultures in Sweden 2001-2007, reported to EARSS. Swedres 2007

Figure 4.1.14. Resistance rates (resistant isolates in percent of all K. pneumoniae isolates) for four groups of antibiotics 2005-2007. Swedres 2007

Table 4.1.8. K. pneumoniae from blood cultures in Sweden 2005-2007, reported to EARSS. Swedres 2007

Figure 4.1.15. Resistance rates (resistant isolates in percent of all P. aeruginosa isolates) for four groups of antibiotics 2005-2007. Swedres 2007

Table 4.1.9. P. aeruginosa from blood cultures in Sweden 2005-2007, reported to EARSS. Swedres 2007

Table 4.1.10. H. pylori University Hospitel MAS, Malmö, Sweden 2001-2007. Swedres 2007

Table 4.1.11. C. jejuni/coli University Hospitel MAS, Malmö, Sweden 2001-2007. Swedres 2007

Table 4.1.12. Antibiotic resistance rates (%) and β-lactamase production of Swedish N. gonorrhoeae strains from 2001-2007. Swedres 2007

Table 4. 1. 13. Drug resistant tuberculosis in Sweden Table 4.1.13. Drug resistant tuberculosis in Sweden. Resistance among initial isolates of M. tuberculosis or africanum to at least one of the four drugs: isoniazid, rifampicin, ethambutol or pyrazinamide. Swedres 2007